XML 39 R31.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Basis of Presentation and Significant Accounting Policies - Additional Information (Detail) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Mar. 31, 2024
Dec. 31, 2023
Other Commitments [Line Items]            
Impairment of intangible assets $ 0 $ 0 $ 0 $ 0    
Intangible assets, net 107,859   107,859     $ 65,490
Amortization of intangible assets     7,631 1,364    
Neuren Pharmaceuticals Limited [Member] | License Agreements [Member]            
Other Commitments [Line Items]            
Finite-Lived Intangible Assets, Amortization Expense, Remainder of 2024 4,700   4,700      
Amortization of intangible assets 2,300 $ 1,400 7,600 $ 1,400    
Finite-Lived Intangible Assets, Amortization Expense, Subsequent year $ 9,400   $ 9,400      
FDA Approval Of DAYBUE [Member] | Neuren Pharmaceuticals Limited [Member] | License Agreements [Member]            
Other Commitments [Line Items]            
Intangible assets, net         $ 119,600